XRTX Stock Summary and Trading Ideas (Xortx Therapeutics | NASDAQ:XRTX)

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

Xortx Therapeutics trades on the NASDAQ stock market under the symbol XRTX.

As of February 19, 2026, XRTX stock price was flat at $0.39 with 36,420 million shares trading.

XRTX has a beta of 0.54, meaning it tends to be less sensitive to market movements. XRTX has a correlation of 0.01 to the broad based SPY ETF.

XRTX has a market cap of $2.72 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, XRTX traded as high as $8.01 and as low as $.38.

XRTX has underperformed the market in the last year with a price return of -57.2% while the SPY ETF gained +13.1%. XRTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -29.2% and -20.4%, respectively, while the SPY returned +4.0% and -0.2%, respectively.

XRTX support price is $.36 and resistance is $.42 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XRTX shares will trade within this expected range on the day.